Cargando…
Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis
This retrospective study investigated factors influencing the portal vein thrombosis (PVT) volume and recurrence in 52 cirrhosis patients with PVT from November 2008 to September 2018. All patients were treated with danaparoid sodium with or without additional antithrombin III. Blood platelet counts...
Autores principales: | Suda, Tsuyoshi, Takatori, Hajime, Hayashi, Takehiro, Horii, Rika, Nio, Kouki, Terashima, Takeshi, Iida, Noriho, Kitahara, Masaaki, Shimakami, Tetsuro, Arai, Kuniaki, Yamashita, Taro, Yamashita, Tatsuya, Mizukoshi, Eishiro, Honda, Masao, Okumura, Kenichiro, Kozaka, Kazuto, Kaneko, Shuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555202/ https://www.ncbi.nlm.nih.gov/pubmed/32899804 http://dx.doi.org/10.3390/life10090177 |
Ejemplares similares
-
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
por: Hayashi, Takehiro, et al.
Publicado: (2019) -
Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis
por: Suda, Tsuyoshi, et al.
Publicado: (2023) -
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
por: Hashiba, Tomomi, et al.
Publicado: (2020) -
Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8(+) T cells
por: Mizukoshi, Eishiro, et al.
Publicado: (2022) -
Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation
por: Kitahara, Masaaki, et al.
Publicado: (2020)